Fig. 1From: A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancerPopulation attrition after applying inclusion/exclusion criteria and propensity score matching. Cap, capecitabine; Gem, gemcitabine; NVB, vinorelbine; 5fu, 5-fluorouracil; EADM, epirubicinBack to article page